23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.

23andMe announces layoffs, will cut 40% of workforce The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach.

In 2021, 23andMe went public through a merger with a special purpose acquisition company, or SPAC. It later expanded into drug-discovery and weight-loss sectors.

23andMe announces layoffs, will cut 40% of workforce The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach.

23andMe announces layoffs, will cut 40% of workforce The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach.

23andMe announces layoffs, will cut 40% of workforce The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach.

23andMe announces layoffs, will cut 40% of workforce The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach.

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach, several rounds of previous layoffs and piling losses that ...

23andMe announces layoffs, will cut 40% of workforce The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach.

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach.